SDH-Engine

Drug Repurposing Engine

DashboardDrug CandidatesAI HypothesesResearch FeedClinical TrialsAbout / Methods

Targeting SDH-deficient GIST, paraganglioma, pheochromocytoma, RCC

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

5 candidates mapped to SDH-deficient disease pathways

All (38)established (6)clinical trial (5)preclinical (14)theoretical (13)
Rogaratinib
clinical trial

Pan-FGFR inhibitor (FGFR1/2/3/4)

Fgfr SignalingEpigenetic Dysregulation
GIST
Evidence Score
76
1 trial
Temozolomide

Temodar, Temodal

clinical trial

Alkylating agent

Epigenetic Dysregulation
PPGL/PCC
Evidence Score
68
FDA Approved
Tazemetostat

Tazverik

clinical trial

EZH2 inhibitor (PRC2 inhibitor)

Epigenetic Dysregulation
All SDH tumors
Evidence Score
65
FDA Approved1 trial
Telaglenastat

CB-839

clinical trial

Glutaminase inhibitor

Glutamine Dependency
All SDH tumors
Evidence Score
60
2 trials
[212Pb]VMT-α-NET
clinical trial

Alpha-particle SSTR2-targeted radioligand therapy (RLT)

Sstr2 Somatostatin VulnerabilitySdh Driven Hrd
PPGL/PCC
Evidence Score
28
2 trials